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a delayed basis. BMT centers are more likely to be a source of
referral than eye care providers. There is now increased
availability of autologous serum, scleral lenses, and PROSE
treatment. Increasing awareness among these BMT clini-
cians, eye care providers, and patients presents an opportu-
nity for impact as far as improvement QOL for HSCT
survivors.213
Integrating Palliative/Supportive Care Concepts in the
Blood and Marrow Transplant Setting
Pamela Rowland. Palliative and Supportive Care, Children's
of Alabama, Birmingham, AL
The availability of Blood and Marrow Transplant (BMT)
can provide hope and possibly life for patients with certain
acute and chronic diseases that have no hope for cure.
Unfortunately treatments that are necessary to achieve
a cure can illicit untoward symptoms that seriously impact
quality of life (QOL). While the goal of treatmentmay be cure,
the challenge of treatment becomes managing the burden of
those symptoms andmaintaining a QOL that makes that cure
worth the journey.
Symptom burden in the transplant setting presents
a challenge to both the patient and the medical team. High
dose chemotherapies with high emetogenic potential can
illicit severe nausea and vomiting both acute and delayed.
Some acute complications of transplant include mucositis,
anorexia, pain, graft versus host disease and immunosup-
pression. Acute symptoms can become chronic. To address
symptom burden it seems logical that the experts in each of
these disciplines, BMT and palliative/ supportive medicine,
should partner to give these patients the best possible
outcome.
Obstacles to excellent palliative/supportive care in the
BMT setting can occur when consults are based on clinician
values, rather than patient needs. Many clinicians mistakenly
believe palliative/supportive care translates to end of life
care. The World Health Organization reports palliative/
supportive care is applicable early in the course of illness, in
conjunction with other therapies that are intended to
prolong life, such as chemotherapy or radiation therapy, and
includes those investigations needed to better understand
and manage distressing clinical complications.
The intent of this paper is to outline a proposal for the
integration of palliative/supportive care concepts in the BMT
setting that can facilitate the transformation of the latest
knowledge into strategies that help to manage the burden of
symptoms in the BMT setting.214
Body Mass Index as an Indicator of Prognosis in Patients
Undergoing Allogeneic Hematopoietic Stem Cell
Transplantation: A Single Institution Experience
Guillermo Jose Ruiz-Delgado, Julia A. Lutz-Presno,
Carlos Alarcon-Urdaneta, Guillermo J. Ruiz-Arguelles. Centro de
Hematologia y Medicina Interna, Clinica Ruiz, Puebla, Mexico
Both obesity and malnutrition are considered risk factors
for complications and increased relapse and nonrelapse
mortality in hematopoietic stem cell transplantation (HSCT).
An inferior outcome after allogeneic HSCT has been reported
in obese adult patients in both allogeneic and autologous
HSCT: Overweight individuals seem to develop more
complications of graft versus host disease and moreinfections than its normal counterparts. Between March
1996 and December 2010, a total of 138 patients received an
allogeneic HSCT in the Centro de Hematología y Medicina
Interna of the Clinica Ruiz. Patients were stratiﬁed according
to pretransplantation body mass index (BMI) values: 17
patients had low BMI, 62 had normal BMI and 59 patients
had high BMI. Median overall survival (OS) for these three
groups were respectively 9, 12 and 22 months. Patients with
a low BMI had a lower OS than those with a normal BMI (58-
month OS of 24% versus 32%), whereas patients with an
increased BMI had a better outcome (median OS of 22
months and 43% OS at 130months) than those with a normal
BMI. Our ﬁndings demonstrate a correlation between pre-
transplantation BMI and posttransplantation survival and
should provide insight into how to better manage nutritional
support for patients undergoing HSCT.215
Factors Impacting Family Decisions to Pursue
Transplantation for Children with Sickle Cell Disease
Amanda L. Thompson 1, Eileen Twohy 1, Jackie Dioguardi 1,
Emily Riehm Meier 2. 1 Children's National Medical Center,
Washington, DC; 2 Division of Hematology, Children's National
Medical Center, Washington, DC
Background: The only cure currently available for sickle cell
disease (SCD) is hematopeotic stem cell transplantation
(HSCT). Barriers preventing widespread application of HSCT
include limited donor pools and lack of family education
about HSCT. To our knowledge, no studies have examined
medical and psychosocial factors that inﬂuence families'
decisions about whether or not to pursue HSCT for their child
with SCD.
Methods: Surveys created by members of the Sickle Cell,
Blood and Marrow Transplantation, and Psychosocial teams
were distributed to family members attending an education
symposium about HSCT for SCD at a large metropolitan
hospital. Surveys were anonymous, optional, and approved
by the Institutional Review Board; participants were entered
into a gift card drawing. On a scale from 0 (“not important at
all”) to 3 (“very important”), participants rated the relative
importance of 17 factors that may impact the decision to
pursue HSCT.
Results: Thirty-four attendees completed surveys; 15% were
parents/guardians of patients who had already had a trans-
plant (n ¼ 5), 73% were parents/guardians of patients who
had not had a transplant (n ¼ 25), and 12% were “other”
family members (n ¼ 4; e.g., aunt, grandmother). Items that
were consistently rated important (i.e., >80% of respondents
rated them “somewhat important,” “important,” or “very
important”) represented multiple domains, including: HSCT-
related risks (e.g., death, infertility, transplant failure, GVHD),
prevention of SCD complications, medical team interactions
(e.g., hematologist recommendation, trust in medical team),
and psychosocial concerns (e.g., emotional strain on patient/
parents, social support). Items not consistently rated
important included ﬁnancial strain, impact on sibling donor,
child losing hair, child missing school, and religious beliefs.
Mean importance ratings were highest for risk of death (M ¼
2.91) and prevention of SCD complications (M ¼ 2.82) and
lowest for religious beliefs (M ¼ .68) and child losing hair
(M ¼ 1.00). See for importance ratings of individual survey
items. There were few differences between ratings of family
members who had been through transplant and those who
had not.
Conclusions: When considering HSCT for SCD, parents and
caregivers report HSCT-related risks, interactions with
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their decision. Results emphasize the importance of ongoing
education for families, the role of the family-physician rela-
tionship, and the value of psychosocial support throughout
the transplant process. Although the current study is limited
by a small convenience sample that may not be representa-
tive of the large sickle cell population (i.e., self-selection to
attend the symposium may indicate greater interest in
pursuing transplant), these ﬁndings provide important
insight into the complexity of family decisions about HSCT.216
Late Pneumocystis Pneumonia After HSCT: Atypical
Presentation and Lack of Correlation with CD4 Count
Taylor Tiffani, Daniele Avila, Steven Z. Pavletic, Daniel Fowler,
Nancy Hardy, David Halverson, Juan Gea-Banacloche.
Experimental Transplantation and Immunology Branch, NCI,
Bethesda, MD
Duration of Pneumocystis pneumonia (PCP) prophylaxis
after allogeneic HSCT is not well deﬁned. Guidelines
recommend at least six months, and longer for patients on
immunosuppression. We report six cases of PCP that
happened late after allo-HSCT (median 36 months, range 19-
80). All had received peripheral blood HSCT: three from
matched sibling donors (MRD), and three from matched
unrelated donors (MUD) (the latter with alemtuzumab
conditioning). At the time of PCP, three patients (#3, #4, #5)
were not on immunosuppression and had no active graft
versus host disease (GVHD). Their mean CD4 T cell count was
569 (range 411-664). The other three had late-acute (#6,
post-DLI) or chronic (#1 and #2) GVHD. Only #1 was on
prednisone (< 0.5 mg/kg); #2 and #6 were on MMF alone.
Their mean CD4 T cell count was 210 (range 86-380). #1 and
#5 were on PCP prophylaxis (dapsone, atovaquone).
Clinical presentationwas atypical. Subacute fever without
shortness of breath (SOB) was most common. Patient #1 was
asymptomatic, with diffuse inﬁltrates found on restaging
chest CT. Only #2 presented with acute SOB and hypoxemia.Tabel 1
Patient #
Age, gender
1
46M
2
35M
3
51M
Disease DLBCL HD DLBCL
Months after
Tx at PCP
36 58 36
HSCT donor MUD (campath) MRD MUD (campa
aGVHD GI No GI, skin
cGVHD Mouth, upper GI,
eyes
Extensive No
GVHD Rx Prednisone,
topical
steroids
MMF, azithromycin,
montelukast
None
CD4 (334-1556) 86 380 411
PCP prophylaxis Dapsone No No
Presentation Asymptomatic Acute SOB cough Subacute fev
CT Diffuse reticular
and ground
glass opacity
Ground glass opacities,
focal consolidation in both
upper lobes, and RML
Diffuse multi
ground glass
reticular opa
in both lungs
BAL GMS+ GMS+ GMS+
DFA+ DFA+ DFA+
PCR+ PCR+ PCR+All patients had ground-glass opacities, but these were pat-
chy/multifocal (n¼4) rather than diffuse (n¼2). PCR was
more sensitive than DFA or GMS. Response to TMP/SMX (Â
steroids) was uniformly positive.
Conclusion: PCP may occur late after transplant, even in the
absence of immunosuppressive therapy, active GVHD or
CD4-T lymphopenia. Patchy ground-glass opacities and
nonspeciﬁc inﬁltrates are the common radiologic feature.
Post-transplant CD4 count does not seem to be useful to
predict PCP or the need for prophylaxis. It is possible that
a qualitative immune T cell defect accounts for late PCP.217
Palliative Care Intergration into an Acute Leukemia and
Bone Marrow Transplant Program
Amy Velasquez 1, Erin Winters 2. 1 BMT, University of Kansas
Hospital, Westwood, KS; 2 BMT, University of Kansas Hospital
Advancements in bonemarrow transplant (BMT) have led
to an increasing number of patients surviving both their
initial cancer diagnosis, and the aggressive treatment used to
cure the cancer. However for most patients, this cure comes
at a signiﬁcant cost. Complications from BMT and chemo-
therapy regimens lead to chronic conditions, which impact
both quality and quantity of life. Palliative care is not only for
dying patients; It provides support for symptom manage-
ment, emotional support, and advance care planning for any
patient and family member facing serious illness. Most
importantly, palliative care improves communication
between the primary physician and family members, and
assists with sometimes very difﬁcult life questions. Clinical
integration of two palliative care MD clinic sessions have
been embedded into the BMT clinic workﬂow in February
2012. The purpose is to measure outcome support for the
staff, patient and family members on an outpatient basis and
increase palliative care physician referrals from the Bone
Marrow Transplant program. In addition, a goal is to increase
patient/family and team planning for end of life care and to
decrease the number of hospital deaths among Bone marrow4
46M
5
55M
6
54M
MZL TCL CLL
19 80 27
th) MUD (campath) MRD MRD
No Skin Skin, liver post-DLI
No No No
None None MMF, topicals
631 664 164
No Atovaquone No
er Subacute fever Subacute fever;
cough
Subacute fever;
cough
focal
and
cities
.
Bilateral ground
glass inﬁltrates.
Multi focal nodular
and diffuse
inﬁltrates.
RLL consolidation and
patchy ground glass
opacities in RML
and LLL.
GMS- GMS- GMS-
DFA- DFA- DFA+
PCR+ PCR+ PCR+
